Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a 0.5 mg per vial injectable solution for intravenous use. It is employed in cardiac imaging to assess myocardial perfusion and viability in patients evaluated for coronary artery disease.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Myoview, containing tetrofosmin, is used in cardiac imaging to evaluate myocardial blood flow and viability.

Coronary artery disease: enables detection of perfusion defects during stress and rest SPECT imaging. Myocardial viability assessment: helps differentiate viable from non‑viable myocardium for revascularization decisions. Stress‑rest cardiac SPECT imaging: provides high‑quality images for evaluating regional perfusion under pharmacologic or exercise stress.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. - Flushing: temporary warmth or redness of skin.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hypotension: sudden drop in blood pressure. - Cardiac arrhythmia: abnormal heart rhythm observed in rare cases.

When using Myoview, several precautions should be observed to ensure patient safety and product integrity.

Patient screening: assess for known hypersensitivity to technetium‑99m compounds before administration. Pregnancy considerations: avoid use in pregnant women unless the diagnostic benefit outweighs potential risk. Breastfeeding guidance: advise temporary cessation of breastfeeding or discard milk for 24 hours after injection. Drug interactions: review concurrent medications that may affect myocardial perfusion or radionuclide distribution. Radiation safety: follow institutional protocols to limit radiation exposure to staff and patients. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with certain agents that influence cardiac perfusion or radionuclide handling.

Major Interactions (Avoid): - Beta‑blockers: can blunt stress‑induced heart rate response, affecting image interpretation. - Calcium channel blockers: may alter myocardial blood flow and reduce tracer uptake.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may change perfusion patterns, requiring timing adjustments. - Thyroid hormones: can affect technetium metabolism, necessitating monitoring. - Chemotherapeutic agents: potential additive radiation exposure; evaluate risk‑benefit.